Metaraminol

Metaraminol
Clinical data
Pregnancy; category	AU: C ; US: C (Risk not ruled out) ; ;
Routes of; administration	Intravenous
ATC code	C01CA09 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	~45%
Metabolism	Hepatic
Identifiers
	IUPAC name 3-[(1R,2S)-2-amino-1-hydroxy-propyl]phenol;
CAS Number	54-49-9;
PubChem CID	5906;
DrugBank	APRD00555;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C9H13NO2
Molar mass	167.205 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Metaraminol (INN, trade name Aramine) is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α₁-adrenergic receptor agonist with some β effect.

Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.^[1]^[2]^[3]

References

↑ McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. PMID 15703094.
↑ Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. PMID 2258979.
↑ Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.

Template:Adrenergic and dopaminergic agents

Template:WikiDoc Sources

[McDonald-1] McDonald M, Santucci R (2004). "Successful management of stuttering priapism using home self-injections of the alpha-agonist metaraminol". Int Braz J Urol. 30 (2): 121–2. PMID 15703094.

[Koga-2] Koga S, Shiraishi K, Saito Y (1990). "Post-traumatic priapism treated with metaraminol bitartrate: case report". J Trauma. 30 (12): 1591–3. PMID 2258979.

[Block-3] Block T, Sturm W, Ernst G, Staehler G, Schmiedt E (1988). "[Metaraminol in therapy of various forms of priapism]". Urologe A. 27 (4): 225–9. PMID 3140463.

[1]

[2]

[3]

Clinical data

Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	Intravenous
ATC code	C01CA09 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	n/a
Protein binding	~45%
Metabolism	Hepatic
Identifiers
IUPAC name 3-[(1R,2S)-2-amino-1-hydroxy-propyl]phenol
CAS Number	54-49-9
PubChem CID	5906
DrugBank	APRD00555
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₉H₁₃NO₂
Molar mass	167.205 g/mol

Metaraminol

Overview

References

Navigation menu